We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Immupharma Plc | IMM | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| -0.14 | -6.86% | 1.90 | 16:35:20 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 2.00 | 2.00 | 2.01 | 1.90 | 2.04 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 07/2/2024 14:49 by blackhorse23 https://www.alliance |
Posted at 31/8/2023 09:23 by lord loads of lolly Yup, it smacks of desperation when the RNS keeps trying to make out there'll be positive newsflow going forward. And that this in turn SHOULD lead to an improved share price. Let's just look at the past sharing agreements shall we? And I quote directly from the RNS:"The Sharing Agreement is similar in structure to those undertaken by the Company with Lanstead in February 2016, June 2019, March 2020, December 2021 and August 2022 respectively. The first three of these arrangements have completed their settlement periods. The February 2016 agreement yielded a net gain to ImmuPharma of approximately £0.6 million more than originally subscribed by Lanstead. The June 2019 and March 2020 agreements yielded approximately £0.9 million and £1.0 million less than originally subscribed by Lanstead respectively. The fourth arrangement runs to March 2024 and is currently yielding approximately £1.1 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date. The fifth arrangement runs to August 2024 and is currently yielding approximately £0.3 million less than the pro rata amount originally subscribed by Lanstead on cumulative settlements to date." So that's five agreements in total, one of which yielded a positive result (+ £0.6m approx). Currently the other four - of which two are already complete - have yielded a cumulative LOSS of £3.3m versus the current share price. WHAT A TRIUMPH! Given the above, how many private investors are likely to beat a path to the Winterflood Retail Access Platform so they can subscribe to the Retail Offer? Answers on a postcard please. Clue: the answer may be a nice round figure. At least it can't be negative. Unlike the Sharing Agreement outcomes to date. |
Posted at 22/6/2023 10:26 by lord loads of lolly supernumerary - McCarthy has frequently misled investors in presentations & interviews. Remember the time he told us they could plough on, regardless of the FDA outcome? Only to find the FDA gave them comprehensive guidance (which it would have been commercial suicide to ignore, as any trial was sure to fail, short of following the guidance). So now - belatedly - they are. And you STILL respect him?! |
Posted at 14/11/2022 18:32 by neo26 Its true he did say that in interview. Now we know why all those warrants price reduced to 5p, they expected this but mislead investors. |
Posted at 12/10/2022 12:46 by lord loads of lolly colsmith - saying they could progress a P3 regardless is NOT the same as saying the FDA had already given approval (which Nobby implies). Hence my request for a link to the interview in question so we can all listen to exactly what Tim said at the time. It's important because if he can be proved to have misled investors, there's a case for him to answer to the FCA. |
Posted at 11/10/2022 14:45 by lord loads of lolly colsmith - True, though due diligence is always just a best estimate of how things will pan out. Not being privvy to past meetings between the FDA & Avion/IMM, investors can't really say if the FDA's current "reservations" were to be anticipated. For all we know, they may have given out completely different signals previously (though I somehow doubt it!). I don't think Avion fears the costs of jumping through further hoops - followed by a successful P3 trial - would outweigh eventual US rights revenues. Trouble is, they can't tell whether the next P3 WOULD be successful, even if they jumped through all the hoops. Therein lies their dilemma. Which is probably why it's taking them so long to update us. |
Posted at 14/9/2022 21:05 by pretax2 May I humbly suggest taking a look at Plant Health Care (PHC) to get your money back in the next two years. Their plant biostimulants do work - brilliantly. They substantially increasing yields for growers, they're growing big time globally, no more raises and looking towards $30m sales by 2025. The climate change and sustainability agenda, as well as a growing food crisis with high fertilizer costs and increasing competiion for land from Bio fuels, are helping the stars align. Oh, and the shareprice hasn't broken out yet, but the heard are gathering slowly. Investors only, this isn't an overnight boom and bust share.Just a suggestion, no pump intended (or needed really). If you're not interested, please continue the fight here. Usual caveats apply. DYOR. |
Posted at 31/8/2022 08:03 by lord loads of lolly Share price between now & announcement day will show whether investors view this as postponement of good news or a stay of execution. |
Posted at 30/8/2022 10:23 by lord loads of lolly Meanwhile, investors are getting twitchy. When I first checked 15 minutes ago, the bid was 6.489p. Currently (10.22am) it's 6.24p. |
Posted at 03/8/2022 22:52 by supernumerary waterloo - it's no use judging McCarthy from the point of view of a PI trader. If you look at it from the point of view of the company - who pay his salary after all - he's played a blinder since the day he arrived. Without him IMM would have been dead in the water years ago. It's the science and the scientists that have let investors down, not McCarthy who, let's face it, is the only thing that's kept them from the knacker's yard. Before he arrived the company was completely moribund, with a clueless management sitting on a depreciating asset with no idea how to move it forward.This deal looks ugly, but so did the last Lanstead deal and in fact it worked out very well for IMM. If this is structured like the last one - haven't really looked at it - then everything depends on the news flow: positive and everyone's happy, but negative and it's an excruciating death spiral. But McCarthy's just doing what he has to in the face of a worthless (if you're to believe what some say) asset. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
